Success Metrics

Clinical Success Rate

88.2%

Based on 30 completed trials

Completion Rate

88%(30/34)

Active Trials

4(9%)

Results Posted

60%(18 trials)

Terminated

4(9%)

Phase Distribution

Ph phase_1

11%

Ph phase_2

33%

Ph phase_4

Ph early_phase_1

Ph not_applicable

40%

Ph phase_3

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution45 total trials

Early Phase 1First-in-human

4(8.9%)

Phase 1Safety & dosage

5(11.1%)

Phase 2Efficacy & side effects

15(33.3%)

Phase 3Large-scale testing

1(2.2%)

Phase 4Post-market surveillance

2(4.4%)

N/ANon-phased studies

18(40.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.7%

30 of 35 finished

Non-Completion Rate

14.3%

5 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(4)

Completed(30)

Terminated(5)

Other(6)

Detailed Status

Completed30

unknown6

Terminated4

Recruiting3

Active, not recruiting1

Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

88.2%

Most Advanced

Phase 4

Trials by Phase

Early Phase 14 (8.9%)

Phase 15 (11.1%)

Phase 215 (33.3%)

Phase 31 (2.2%)

Phase 42 (4.4%)

N/A18 (40.0%)

Trials by Status

unknown613%

active_not_recruiting12%

terminated49%

completed3067%

withdrawn12%

recruiting37%

Recent Activity

4 active trials

Showing 5 of 45

recruitingnot_applicable

Oxytocin's Effects on Real Time-fMRI Neurofeedback Training of Anterior Insula Activity

NCT07559656

recruitingphase_2

Intranasal Oxytocin for the Treatment of Children and Adolescents With Autism Spectrum Disorders (ASD)

NCT01908205

View all 45 trials

Clinical Trials (45)

Showing 20 of 45 trialsScroll for more

NCT07559656Not Applicable

Oxytocin's Effects on Real Time-fMRI Neurofeedback Training of Anterior Insula Activity

Recruiting

NCT07053774Phase 2

Intranasal and Intravenous Oxytocin for Analgesia to Noxious Heat Pain

Recruiting

NCT03593473Phase 2

Inhaled Oxytocin and HPA Axis Reactivity

Completed

NCT01788072Phase 2

INtranasal OXyTocin for the Treatment of Autism Spectrum Disorders

Completed

NCT01908205Phase 2

Intranasal Oxytocin for the Treatment of Children and Adolescents With Autism Spectrum Disorders (ASD)

Completed

NCT05312008Phase 2

Does Oxytocin Alter Tolerance to or Motivation for Alcohol

Terminated

NCT05672667Phase 1

A Pharmacokinetic Study of Intravenous and Intranasal Oxytocin in Healthy Subjects

Completed

NCT02737436Not Applicable

Intranasal Oxytocin and Maternal Neglect

Completed

NCT06405737Not Applicable

Oxytocin's Effect on the Advantageous- and Disadvantageous-inequity

Completed

NCT01931033Not Applicable

An Open-Label Trial of Oxytocin in Adolescents With Autism Spectrum Disorders

Completed

NCT02985749Phase 3

A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder

Completed

NCT03566069Phase 2

Intranasal Oxytocin as Enhancer of Psychotherapy Outcomes in Severe Mental Illness

Active Not Recruiting

NCT05432089Phase 2

The Effects of Oxytocin Administration to Patients and Therapists on Physiological Synchronization

Recruiting

NCT05245708Not Applicable

Effects of Oxytocin on Reinforcement Learning and Interoception

Completed

NCT02127073Phase 2

Pilot Study of Oxytocin and microRNA Identification in NAF, Serum, and Tissue in Women With Breast Cancer

Terminated

NCT04007224Phase 1

Umbilical Cord Blood vs Personalized Treatments for Improving Autistic Disorder

Completed

NCT05920707Not Applicable

Common and Differentiated Representations Between Social Exclusion and Social Separation

Unknown

NCT02255357Phase 2

Investigation of Intranasal Oxytocin on Relapse Risk in Cocaine-dependent Patients.

Completed

NCT05265806Not Applicable

The Effects of Oxytocin Treatment on Social Touch

Completed

NCT02493426Phase 2

Single Dose Intranasal Oxytocin and Cognitive Effects in Autism

Completed

Drug Details

Intervention Type: DRUG
Total Trials: 45